Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Cuts Q1 Loss Despite No Revenues

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it generated no revenues for the first quarter of 2011, compared to $125,000 for the first quarter of 2010.

The Tel Aviv, Israel-based firm, which makes computational biology tools and is developing therapeutics, reported a net loss of $1.9 million, or $.06 per share, for the three-month period ended March 31. For Q1 2010, its net loss was $2.7 million, or $.08 per share.

Compugen's R&D spending in the quarter was $1.6 million, flat with the prior year. Its marketing, business development, general and administrative costs were $791,000, compared to $1.2 million for Q1 2010.

Compugen finished the quarter with $25.6 million in cash, cash equivalents, restricted cash, and short-term bank deposits.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.